Avastin: Quick hit didn’t pay off

Genentech Inc. took a gamble with its Avastin anti-VEGF antibody in metastatic breast cancer and it failed to pay off last week, as the compound failed to show progression-free survival in a Phase III trial. But by taking on a population with more advanced disease and

Read the full 464 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers